e-learning
resources
Vienna 2009
Monday, 14.09.2009
Translational research/biomarkers
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Long-acting anticholinergic, aclidinium bromide (AB) significantly attenuates airway inflammation and hyper-responsiveness in an
AF
-induced murine model of asthma
G. Damera, C. Philip, W. Jester, F. Homer, J. Meiqi, J. Freire, R. Panettieri (Philadelphia, Jersey City, United States Of America)
Source:
Annual Congress 2009 - Translational research/biomarkers
Session:
Translational research/biomarkers
Session type:
E-Communication Session
Number:
2939
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Damera, C. Philip, W. Jester, F. Homer, J. Meiqi, J. Freire, R. Panettieri (Philadelphia, Jersey City, United States Of America). Long-acting anticholinergic, aclidinium bromide (AB) significantly attenuates airway inflammation and hyper-responsiveness in an
AF
-induced murine model of asthma. Eur Respir J 2009; 34: Suppl. 53, 2939
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Acute reversal of allergen-induced airway hyperresponsiveness (AHR) by olodaterol is synergistically enhanced by tiotropium bromide
Source: Annual Congress 2011 - Models of disease and drug actions
Year: 2011
Protection against allergen-induced airway hyperresponsiveness (AHR) by olodaterol in guinea pigs is synergistically enhanced by tiotropium
Source: Annual Congress 2012 - Animal models of asthma and COPD and late-breaking abstracts on RCT in asthma and COPD
Year: 2012
Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma
Source: Eur Respir J 2002; 20: 1080-1087
Year: 2002
Effect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma
Source: Eur Respir J 2001; 17: 374-379
Year: 2001
Budesonide prevents but does not reverse sustained airway hyperresponsiveness in mice
Source: Eur Respir J 2008; 32: 970-978
Year: 2008
Fluticasone furoate, a novel inhaled corticosteroid (ICS), provides sustained protection against amp airway hyperresponsiveness (AHR) in mild asthma
Source: Annual Congress 2009 - New drugs for airways disease
Year: 2009
Effects of budesonide/formoterol maintenance therapy on airway hyperresponsiveness and inflammation in an allergic rat model
Source: Eur Respir J 2004; 24: Suppl. 48, 351s
Year: 2004
Effect of budesonide/formoterol combination on an airway hyperresponsiveness and inflammation model in mice
Source: Eur Respir J 2004; 24: Suppl. 48, 131s
Year: 2004
Single-dose desloratadine and montelukast and allergen-induced late airway responses
Source: Eur Respir J 2009; 33: 1302-1308
Year: 2009
Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison
Source: Eur Respir J 2007; 30: 653-661
Year: 2007
Effects of salbutamol and enantiomers on allergen-induced asthmatic reactions and airway hyperreactivity
Source: Eur Respir J 2005; 25: 864-872
Year: 2005
Montelukast attenuates the airway response to hypertonic saline in moderate-to-severe COPD
Source: Eur Respir J 2003 Dec 01;22(6):926-930
Year: 2003
Comparative study of the effects of tiotropium bromide and budesonide on allergen-induced airway remodeling
Source: Eur Respir J 2006; 28: Suppl. 50, 434s
Year: 2006
Changes in objective markers following inhaled corticosteroids (ICS) in asthmatics with airway hyperresponsiveness (AHR) to mannitol
Source: International Congress 2019 – Airway physiology
Year: 2019
Salmeterol/fluticasone propionate combination (SFC) improves airways hyperresponsiveness (AHR), lung function and symptoms in adult patients with mild asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 262s
Year: 2004
Effects of salmeterol/fluticasone propionate (SFC) on airway inflammation in induced sputum in COPD
Source: Annual Congress 2005 - Effects of anti-inflammatory drugs on COPD
Year: 2005
Roflumilast but not dexamethasone or fluticasone reduces neutrophilic airway inflammation and hyperreactivity in a murine influenza-induced asthma exacerbation model
Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma
Year: 2016
Dissociation of the effects of a steroid on inflammation compared to airway hyperresponsiveness (AHR) in a model of asthma in conscious mice
Source: Eur Respir J 2001; 18: Suppl. 33, 30s
Year: 2001
Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma
Source: Eur Respir J 2002; 20: 66-72
Year: 2002
Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma
Source: Eur Respir J 2002; 20: 853-858
Year: 2002
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept